Literature DB >> 24597863

Assessment of inhomogeneities of repolarization in patients with systemic lupus erythematosus.

Ahmet Avci1, Kenan Demir, Bulent Behlul Altunkeser, Sema Yilmaz, Ahmet Yilmaz, Ahmet Ersecgin, Tarik Demir.   

Abstract

OBJECTIVES: Systemic lupus erythematosus (SLE) is a chronic disease that affects many organ systems and manifests a broad spectrum of laboratory and clinical features. SLE patients have an increased risk of developing cardiovascular disease. The aim of this study was to evaluate inhomogeneities of repolarization by using Tpeak -Tend (Tp-e) interval and Tp-e/QT ratio were measured from the 12-lead surface electrocardiogram (ECG) in patients with SLE. MATERIAL AND
METHOD: This study included 69 SLE patients (69 females; mean age 35.8 ± 10.2) and 57 control subjects (57 females; mean age 34.5 ± 8.9). Transthoracic echocardiographic examination was done in all participants. QT parameters, Tp-e intervals and Tp-e/QT ratio were measured from the 12-lead ECG. These parameters were compared between groups.
RESULTS: No statistically significant difference was found between two groups in terms of basic characteristics. Diastolic function parameters were similar between the two groups (P > 0.05). In electrocardiographic parameters analysis, QT dispersion (QTd) and corrected QT dispersion (cQTd) were significantly increased in SLE patients compared the control group (49.5 ± 16.4 ms vs. 32.8±11.7 ms and 56.7 ± 19.5 ms vs. 36.4 ± 13.1 ms, all P value < 0.001). Tp-e interval and Tp-e/QT ratio were also significantly higher in SLE patients (82.8 ± 18.9 vs. 72.4 ± 17.6 and 0.22 ± 0.05 vs. 0.19 ± 0.05, P = 0.002 and P = 0.001, respectively). Tp-e interval and Tp-e/QT were positively correlated with disease duration (r = 0.29, P = 0.01 and r = 0.24, P = 0.04, respectively).
CONCLUSION: Our study revealed that QTd, cQTd, Tp-e interval and Tp-e/QT ratio increased in patients with SLE. Also, Tp-e interval and Tp-e/QT were positively correlated with disease duration.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  Tp-e interval; Tp-e/QT; arrhythmia; inhomogeneities of repolarization; systemic lupus erythematosus

Mesh:

Year:  2014        PMID: 24597863      PMCID: PMC6932449          DOI: 10.1111/anec.12145

Source DB:  PubMed          Journal:  Ann Noninvasive Electrocardiol        ISSN: 1082-720X            Impact factor:   1.468


  33 in total

Review 1.  Modulation of transmural repolarization.

Authors:  Charles Antzelevitch
Journal:  Ann N Y Acad Sci       Date:  2005-06       Impact factor: 5.691

2.  QT-interval parameters are increased in systemic lupus erythematosus patients.

Authors:  C R L Cardoso; M A O Sales; J A S Papi; G F Salles
Journal:  Lupus       Date:  2005       Impact factor: 2.911

Review 3.  Arrhythmias in systemic lupus erythematosus.

Authors:  Ricardo Alkmim Teixeira; Eduardo Ferreira Borba; Eloisa Bonfá; Martino Martinelli Filho
Journal:  Rev Bras Reumatol       Date:  2010 Jan-Feb

4.  The bimodal mortality pattern of systemic lupus erythematosus.

Authors:  M B Urowitz; A A Bookman; B E Koehler; D A Gordon; H A Smythe; M A Ogryzlo
Journal:  Am J Med       Date:  1976-02       Impact factor: 4.965

Review 5.  Cardiac arrhythmias and conduction disturbances in autoimmune rheumatic diseases.

Authors:  P M Seferović; A D Ristić; R Maksimović; D S Simeunović; G G Ristić; G Radovanović; D Seferović; B Maisch; M Matucci-Cerinic
Journal:  Rheumatology (Oxford)       Date:  2006-10       Impact factor: 7.580

6.  Novel electrocardiographic parameters of altered repolarization in uncomplicated overweight and obesity.

Authors:  Annabella Braschi; Maurizio G Abrignani; Vincenzo C Francavilla; Giuseppe Francavilla
Journal:  Obesity (Silver Spring)       Date:  2010-10-21       Impact factor: 5.002

7.  Risk factors for cardiovascular disease in systemic lupus erythematosus.

Authors:  E Svenungsson; K Jensen-Urstad; M Heimbürger; A Silveira; A Hamsten; U de Faire; J L Witztum; J Frostegård
Journal:  Circulation       Date:  2001-10-16       Impact factor: 29.690

8.  Cardiac dysfunction in patients with systemic lupus erythematosus and antiphospholipid syndrome.

Authors:  Daphna Paran; Dan Caspi; David Levartovsky; Ori Elkayam; Ilana Kaufman; Irena Litinsky; Gad Keren; Bella Koifman
Journal:  Ann Rheum Dis       Date:  2006-11-01       Impact factor: 19.103

9.  Prolongation of the corrected QT interval in adult patients with anti-Ro/SSA-positive connective tissue diseases.

Authors:  Pietro Enea Lazzerini; Maurizio Acampa; Francesca Guideri; Pier Leopoldo Capecchi; Valeria Campanella; Gabriella Morozzi; Mauro Galeazzi; Roberto Marcolongo; Franco Laghi-Pasini
Journal:  Arthritis Rheum       Date:  2004-04

10.  Association between Tp-e/QT ratio and prognosis in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.

Authors:  Xiangmei Zhao; Zhouliang Xie; Yingjie Chu; Lei Yang; Wenkai Xu; Xianzhi Yang; Xiaoyu Liu; Lixiao Tian
Journal:  Clin Cardiol       Date:  2012-06-27       Impact factor: 2.882

View more
  3 in total

1.  New markers for ventricular repolarization in coronary slow flow: Tp-e interval, Tp-e/QT ratio, and Tp-e/QTc ratio.

Authors:  Kayihan Karaman; Fatih Altunkaş; Mustafa Çetin; Metin Karayakali; Arif Arısoy; Ilker Akar; Cemil Zencir; Barış Aygüç; Ataç Çelik
Journal:  Ann Noninvasive Electrocardiol       Date:  2014-09-30       Impact factor: 1.468

2.  Evaluation of inhomogeneities of repolarization in patients with psoriasis vulgaris.

Authors:  Korhan Soylu; Sinan İnci; Gökhan Aksan; Gökay Nar; Esra Pancar Yüksel; Hande Serra Ocal; Mustafa Çapraz; Serkan Yüksel; Mahmut Şahin
Journal:  Arch Med Sci       Date:  2016-10-24       Impact factor: 3.318

3.  Assessment of myocardial repolarisation parameters in patients with familial Mediterranean fever.

Authors:  Kayihan Karaman; Metin Karayakali; Ertuğrul Erken; Ahmet Demirtaş; Mustafa Öztürk; Fatih Altunkaş; Arif Arisoy; Oğuzhan Ekrem Turan; Köksal Ceyhan; Ataç Çelik
Journal:  Cardiovasc J Afr       Date:  2017 May/Jun       Impact factor: 1.167

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.